133 related articles for article (PubMed ID: 25728984)
1. Late follow-up of the randomized radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) trial for advanced head and neck cancer.
Heukelom J; Lopez-Yurda M; Balm AJ; Wijers OB; Buter J; Gregor T; Wiggenraad R; de Boer JP; Tan IB; Verheij M; Sonke JJ; Rasch CR
Head Neck; 2016 Apr; 38 Suppl 1():E488-93. PubMed ID: 25728984
[TBL] [Abstract][Full Text] [Related]
2. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
[TBL] [Abstract][Full Text] [Related]
4. Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615.
Robbins KT; Kumar P; Harris J; McCulloch T; Cmelak A; Sofferman R; Levine P; Weisman R; Wilson W; Weymuller E; Fu K
J Clin Oncol; 2005 Mar; 23(7):1447-54. PubMed ID: 15735120
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.
Magrini SM; Buglione M; Corvò R; Pirtoli L; Paiar F; Ponticelli P; Petrucci A; Bacigalupo A; Crociani M; Lastrucci L; Vecchio S; Bonomo P; Pasinetti N; Triggiani L; Cavagnini R; Costa L; Tonoli S; Maddalo M; Grisanti S
J Clin Oncol; 2016 Feb; 34(5):427-35. PubMed ID: 26644536
[TBL] [Abstract][Full Text] [Related]
6. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.
Heukelom J; Hamming O; Bartelink H; Hoebers F; Giralt J; Herlestam T; Verheij M; van den Brekel M; Vogel W; Slevin N; Deutsch E; Sonke JJ; Lambin P; Rasch C
BMC Cancer; 2013 Feb; 13():84. PubMed ID: 23433435
[TBL] [Abstract][Full Text] [Related]
7. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial.
Ghosh-Laskar S; Kalyani N; Gupta T; Budrukkar A; Murthy V; Sengar M; Chaukar D; Pai P; Chaturvedi P; D'Cruz A; Agarwal J
Head Neck; 2016 Feb; 38(2):202-7. PubMed ID: 25224814
[TBL] [Abstract][Full Text] [Related]
8. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer.
Balm AJ; Rasch CR; Schornagel JH; Hilgers FJ; Keus RB; Schultze-Kool L; Ackerstaff AH; Busschers W; Tan IB
Head Neck; 2004 Jun; 26(6):485-93. PubMed ID: 15162349
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy and concomitant intraarterial cisplatin (RADPLAT) for advanced squamous cell carcinomas of the head and neck.
Rabbani A; Hinerman RW; Schmalfuss IM; Amdur RJ; Morris CG; Peters KR; Robbins KT; Mendenhall WM
Am J Clin Oncol; 2007 Jun; 30(3):283-6. PubMed ID: 17551306
[TBL] [Abstract][Full Text] [Related]
10. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT).
Hoebers FJ; Pluim D; Verheij M; Balm AJ; Bartelink H; Schellens JH; Begg AC
Int J Cancer; 2006 Aug; 119(4):750-6. PubMed ID: 16550603
[TBL] [Abstract][Full Text] [Related]
11. Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer.
Furusawa J; Homma A; Onimaru R; Sakashita T; Yoshida D; Hatakeyama H; Mizumachi T; Kano S; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Auris Nasus Larynx; 2015 Dec; 42(6):443-8. PubMed ID: 25933585
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
13. Postoperative radiochemotherapy with weekly cisplatin in patients with head and neck cancer single-institution outcome analysis.
Pala M; Odrazka K; Holeckova P; Vitek P; Kubes J; Podlesak T; Klozar J; Petruzelka L
Neoplasma; 2012; 59(2):129-36. PubMed ID: 22248269
[TBL] [Abstract][Full Text] [Related]
14. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
16. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
[TBL] [Abstract][Full Text] [Related]
17. Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02).
Rischin D; Peters L; Fisher R; Macann A; Denham J; Poulsen M; Jackson M; Kenny L; Penniment M; Corry J; Lamb D; McClure B
J Clin Oncol; 2005 Jan; 23(1):79-87. PubMed ID: 15625362
[TBL] [Abstract][Full Text] [Related]
18. High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: report of a phase II study.
Regine WF; Valentino J; John W; Storey G; Sloan D; Kenady D; Patel P; Pulmano C; Arnold SM; Mohiuddin M
Head Neck; 2000 Sep; 22(6):543-9. PubMed ID: 10941154
[TBL] [Abstract][Full Text] [Related]
19. DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity.
Saksø M; Jensen K; Andersen M; Hansen CR; Eriksen JG; Overgaard J
Radiother Oncol; 2020 Jul; 148():65-72. PubMed ID: 32335364
[TBL] [Abstract][Full Text] [Related]
20. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
